Related Experiment Videos
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction
1Department of Cardiology, Joseph J Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, OH 44195, USA.
Insights
Heparin use in acute myocardial infarction treatment is debated. Intravenous heparin is recommended with tissue plasminogen activator, but not necessarily with streptokinase, to optimize outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heparin's role in acute myocardial infarction (AMI) treatment has been debated for decades.
- Current guidelines recommend intravenous heparin with thrombolytic therapy for AMI.
- Recent research focuses on optimal antithrombotic strategies alongside thrombolysis.
Purpose of the Study:
- To review evidence on adjunctive heparin therapy in AMI treatment.
- To assess heparin's efficacy with different thrombolytic agents.
- To identify optimal heparin dosing for clinical outcomes and safety.
Main Methods:
- Review of angiographic patency trials in AMI.
- Analysis of major thrombolytic mortality reduction trials assessing heparin.
- Examination of new data on activated partial thromboplastin time (aPTT) ranges.
Main Results:
- Intravenous heparin is necessary with tissue plasminogen activator (tPA) for AMI.
- Evidence does not support routine heparin use with streptokinase.
- Maintaining aPTT between 55-70 seconds is crucial for preventing bleeding and improving outcomes.
Conclusions:
- Adjunctive heparin therapy is beneficial with tPA but not conclusively with streptokinase in AMI.
- Optimal heparin dosing, guided by aPTT, is essential for balancing efficacy and safety.
- Further research may refine antithrombotic strategies in AMI management.
Abstract:
For the treatment of acute myocardial infarction, heparin has been a topic of continuing debate for the past four decades. After review of the available data, the American College of Cardiology/American Heart Association Guidelines for the Early Management of Patients with Acute Myocardial Infarction, published in 1990, recommended intravenous heparin administration together or immediately after thrombolytic therapy to maintain the activated partial thromboplastin time approximately 1.5 to 2.0 times the control value for 24 to 72 hours. Over the past five years, with the proven benefits or thrombolytic therapy and antiplatelet therapy, investigators have been in search of the ideal thrombolytic agent as well as the best adjunctive antithrombotic strategy. We review a number of angiographic patency trials as well as the major thrombolytic mortality reduction trials in which adjunctive heparin therapy was directly assessed. These trials established the need for intravenous heparin administration with tissue plasminogen activator, but, on the other hand, do not substantiate the need for either subcutaneous or intravenous heparin use with streptokinase. New data from a large scale trial emphasizes the importance of maintaining the aPTT in the 55-70 second range to prevent bleeding complications and optimize clinical outcomes.